CD99L2, a gene long filed under 'immune system,' turns out to switch on a brain protein nerve cells need, and losing that switch causes X linked spastic ataxia, a rare inherited movement disorder.
When researchers started sorting through nearly 3,000 patients with unexplained movement disorders, they expected to find answers in the usual neuroscience suspects. Instead, the signal kept pointing to a gene biologists had spent years cataloguing as an immune-system player, and that wrong-file turned out to be the whole story.
The gene is CD99L2, and the disorder is X-linked spastic ataxia, a hereditary condition that erodes coordination and muscle control. The discovery, published in Nature Communications by a team led by Dr. Jonasz Weber of Ruhr-University Bochum and Dr. Tobias Haack of Tübingen, gives a genetic name to a slice of patients who, until now, had none.
The cohort that surfaced it came from 26 medical sites across Germany, drawing on 2,811 people referred for unexplained ataxia, hereditary spastic paraplegia, or dystonia, a cluster of related but distinct movement disorders. The team ran 7,241 genetic tests, including 2,041 exome sequencing and 486 genome sequencing cases. Exome sequencing alone returned a diagnostic hit rate of 19.3% in this cohort, and adding structural variants and repeat expansions caught by genome sequencing pushed the yield up another 7.5%. The CD99L2 signal itself came from a broader gene-burden sweep across 13,132 sequenced individuals, with Solve-RD cohort matchmaking narrowing it to the patients whose symptoms matched.
What CD99L2 does, in plain terms, is act as a switch for another protein, CAPN1, that nerve cells need to keep their signaling clean. The paper shows that loss-of-function variants in CD99L2 break its interaction with CAPN1, leave the protease under-activated, and produce transcriptomic signatures of disrupted synaptic function in patient-derived fibroblasts. The immune-system gene was running a piece of nerve-cell communication all along, and when the switch is broken, the wiring stutters.
Inheritance follows the X chromosome, with full penetrance in males and variable penetrance and expressivity in female carriers. A named gene now has real consequences for family counseling. A genetic test can confirm the diagnosis, carriers can be identified earlier, and relatives can be screened with a target in hand instead of a fishing expedition. Those are the concrete gains the Ruhr-University Bochum team is pointing to.
What the finding does not change is treatment. The work is molecular and genetic, in cells and patient DNA, not in clinical trials. The authors also flag calpain-pathway links to Alzheimer's and Parkinson's as a broader-mechanism outlook, not a therapeutic result. A named gene is a foothold: a diagnostic test today, a drug target a future lab can aim at, not a cure on a clinical horizon.
The watch item now is replication outside the German cohort and how many unsolved patients with X-linked spastic ataxia and overlapping disorders will resolve to CD99L2 once other groups start testing for it. That number will decide whether CD99L2 is a niche answer for a few dozen families or a routine entry on the diagnostic panel.